Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial
Authors
Keywords
-
Journal
Lancet Respiratory Medicine
Volume 9, Issue 12, Pages 1427-1438
Publisher
Elsevier BV
Online
2021-10-30
DOI
10.1016/s2213-2600(21)00377-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial
- (2021) Viviane C Veiga et al. BMJ-British Medical Journal
- Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial
- (2021) Serge Bureau et al. Lancet Respiratory Medicine
- Collaborative platform trials to fight COVID‐19: methodological and regulatory considerations for a better societal outcome
- (2021) Olivier Collignon et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
- (2021) Ivan O. Rosas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
- (2021) NEW ENGLAND JOURNAL OF MEDICINE
- Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial
- (2021) François-Xavier Lescure et al. Lancet Respiratory Medicine
- Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial
- (2021) Arvinder S Soin et al. Lancet Respiratory Medicine
- Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial
- (2021) Dongsheng Wang et al. Frontiers of Medicine
- Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
- (2021) Obbina Abani et al. LANCET
- Platform Trials — Beware the Noncomparable Control Group
- (2021) Lori E. Dodd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context
- (2021) Federico Angriman et al. Lancet Respiratory Medicine
- Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
- (2021) et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- IL-6 Receptor Antagonist Therapy for Patients Hospitalized for COVID-19
- (2021) Michael A. Matthay et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
- (2020) Evangelos J. Giamarellos-Bourboulis et al. Cell Host & Microbe
- Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19
- (2020) Tobias Herold et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Elevated Interleukin‐6 and Severe COVID‐19: A Meta‐Analysis
- (2020) Muhammad Aziz et al. JOURNAL OF MEDICAL VIROLOGY
- Elevated interleukin-6 is associated with severity of COVID-19: a meta-analysis
- (2020) Jieyun Zhu et al. JOURNAL OF MEDICAL VIROLOGY
- Characterization of the Inflammatory Response to Severe COVID-19 Illness
- (2020) Oliver J McElvaney et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial
- (2020) Bastiaan Maes et al. Trials
- Is a “Cytokine Storm” Relevant to COVID-19?
- (2020) Pratik Sinha et al. JAMA Internal Medicine
- A score combining early detection of cytokines accurately predicts COVID-19 severity and intensive care unit transfer
- (2020) Carole Nagant et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19
- (2020) et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study
- (2020) José María Galván-Román et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- An inflammatory cytokine signature predicts COVID-19 severity and survival
- (2020) Diane Marie Del Valle et al. NATURE MEDICINE
- Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
- (2020) John H. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia
- (2020) Olivier Hermine et al. JAMA Internal Medicine
- Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia
- (2020) Carlo Salvarani et al. JAMA Internal Medicine
- Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes
- (2020) Daniel E Leisman et al. Lancet Respiratory Medicine
- Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
- (2020) Carlos Salama et al. NEW ENGLAND JOURNAL OF MEDICINE
- An immune-based biomarker signature is associated with mortality in COVID-19 patients
- (2020) Michael S. Abers et al. JCI Insight
- The REDCap consortium: Building an international community of software platform partners
- (2019) Paul A. Harris et al. JOURNAL OF BIOMEDICAL INFORMATICS
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support
- (2008) Paul A. Harris et al. JOURNAL OF BIOMEDICAL INFORMATICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started